Concepedia

Y. Liu

YL

Statistics

Publications

4

Citations

90

H-Index

4

Active since

2005

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Utah

Y. Liu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in natural sciences, biochemistry, and analytical chemistry.

Top concepts

Publications per year

2005–2024

4

Publications

4

Evaluation of a C18 hybrid stationary phase using high-temperature chromatography

Y. Liu, Nelu Grinberg, Karen Thompson et al. · Analytica Chimica Acta · 2005 · 54 citations

, , +8

LBA69 Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study

Ramaprasad Srinivasan, Othon Iliopoulos, W. Kimryn Rathmell et al. · Annals of Oncology · 2022 · 14 citations

, , +9

1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study

Christian Gratzke, Mustafa Özgüroğlu, A. Peer et al. · Annals of Oncology · 2023 · 11 citations · Full text

Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma

Neeraj Agarwal, James Brugarolas, Pooja Ghatalia et al. · Annals of Oncology · 2024 · 11 citations · Full text

1–4 of 4